TY  - GEN
AU  - Van Cutsem,E
AU  - Boni,C
AU  - Tabernero,J
AU  - Massuti,B
AU  - Middleton,G
AU  - Dane,F
AU  - Reichardt,P
AU  - Pimentel,F L
AU  - Cohn,A
AU  - Follana,P
AU  - Clemens,M
AU  - Zaniboni,A
AU  - Moiseyenko,V
AU  - Harrison,M
AU  - Richards,D A
AU  - Prenen,H
AU  - Pernot,S
AU  - Ecstein-Fraisse,E
AU  - Hitier,S
AU  - Rougier,P
TI  - Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
SN  - 1569-8041
PY  - 2015///0824
KW  - Adenocarcinoma
KW  - drug therapy
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Capecitabine
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Drug Administration Schedule
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Organoplatinum Compounds
KW  - Oxaliplatin
KW  - Prospective Studies
KW  - Stomach Neoplasms
KW  - Taxoids
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdu496
ER  -